Abstract

The work of the Vaccine Production Core encompasses efforts in three inter-related areas: live, recombinant vector development;novel adjuvant development;and protein production. The efforts that will be pursued in vector and adjuvant development by this CHAVI group will be described. A rationale for pursuing each technology, the work accomplished to date in developing that technology, and the immediate plans for further development of that technology will be described. This CHAVI group will begin to advance the most promising of these technologies into human clinical testing as early as the second year of the funding period. The protein production component of this core will serve the Haynes RO1, the Shaw SLG project, the Sodroski SLG project, and the Structural Biology Core D. Specifically, we will pursue work in the following areas: 1. Live, recombinant vector development a. Recombinant chimeric adenovirus b. Recombinant mycobacteria c. Recombinant vesicular stomatitis virus 2. Novel adjuvant development a. Polymers b. Chemoattractant cytokines c. TLR agonists 3. Recombinant protein production

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI067854-05
Application #
7896716
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
5
Fiscal Year
2009
Total Cost
$774,582
Indirect Cost

  Institution

Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

Song, Hongshuo; Giorgi, Elena E; Ganusov, Vitaly V et al. (2018) Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun 9:1928
Boelen, Lies; Debebe, Bisrat; Silveira, Marcos et al. (2018) Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Sci Immunol 3:
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Pacheco, Beatriz; Alsahafi, Nirmin; Debbeche, Olfa et al. (2017) Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. J Virol 91:
Fouda, Genevieve G; Eudailey, Joshua; Kunz, Erika L et al. (2017) Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. Mucosal Immunol 10:228-237
Shen, Xiaoying; Bogers, Willy M; Yates, Nicole L et al. (2017) Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. J Virol 91:
Fischetti, Lucia; Zhong, Ziyun; Pinder, Christopher L et al. (2017) The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling. Cytokine 99:287-296
Gelfman, Sahar; Wang, Quanli; McSweeney, K Melodi et al. (2017) Annotating pathogenic non-coding variants in genic regions. Nat Commun 8:236
Mori, Mari; Haskell, Gloria; Kazi, Zoheb et al. (2017) Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease. Mol Genet Metab 122:189-197
Seaton, Kelly E; Vandergrift, Nathan A; Deal, Aaron W et al. (2017) Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight 2:

Showing the most recent 10 out of 395 publications